Confluent Medical 大幅改進供應鏈可見性和效率

安大略省,渥太華–(BUSINESS WIRE)–(美國商業資訊)– Confluent Medical 是醫療器械製造商的材料科學、研發及製造頂尖合作伙伴。該公司運用 Kinaxis 顯著改善了它的端到端供應鏈。這家生產醫療用植入物、微創輸送系統和其他醫療器械的醫療技術創新企業於 2023 年 8 月在 Genpact 的幫助下部署了 Kinaxis®,帶來可見性和效率的顯著提升。 Confluent Medical 專精設計、開發和大規模製造由導管衍生出的各類設備和鎳鈦合金組件,後者是一種具有超彈性和形狀記憶功能的專業金屬合金。該公司在美國和哥斯大黎加擁有8家工廠及2000名員工,其多元產品包括複雜導管、高精度聚合物管和植入式織物。該公司必須有能力對供應鏈的任何環節產生的任何變化做出快速反應。 Confluent Medical 全球供應鏈副總裁 Jeff McCoun表示:「我們的需求峰值幾乎翻了一倍,這通常需要幾個月的時間才能重新同步供應鏈,但我們在幾週內就做到了。在部署 Kinaxis 之前,我們為供應鏈的每個環節單獨製作電子表格,每個人的步調都不一致。如果某個環節發生

JRVR INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages James River Group Holdings, Ltd. Investors to Inquire About Securities Class Action Investigation – JRVR

NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of James River Group Holdings, Ltd. (NASDAQ: JRVR) resulting from allegations that James River may have issued materially misleading business information to the investing public. SO WHAT: If you purchased James River securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting

Summer Announces Combined $68M in Series A Round and Debt Facility to Innovate New Approach to Vacation Homeownership

NEW YORK–(BUSINESS WIRE)–Summer, an innovative approach to short-term rentals and vacation home ownership founded by former Airbnb employees, today announced an $18M funding round from a group of leading investors, including QED and Viola FinTech, as well as a secured debt facility of up to $50M from Setpoint Capital. Contributing investors for the funding round include Lightspeed Venture Partners, 1Sharpe Ventures, CT Innovations, Alumni Ventures, Elizabeth Street Ventures, Merrimac Corporat

Mene Inc. Reports Financial Results for the Third Quarter 2023

TORONTO–(BUSINESS WIRE)–Menē Inc. (TSX-V:MENE) (US:MENEF) (“Menē” or the “Company”), an online 24 karat jewelry brand, today announced financial results for the third quarter ended September 30, 2023. All amounts expressed herein reflect Canadian dollars unless otherwise noted. FINANCIAL HIGHLIGHTS IFRS Revenue of $4.3 million, a decrease of $0.8 million (15%) Year-over-Year (“YoY”). Gross Profit of $0.9 million, with a consistent gross profit margin of 22% YoY. Net loss of $0.7 million durin